{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:04:39Z","timestamp":1793531079584,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ph.D. grants from the Faculty of Health and Medical Sciences, University of Copenhagen Post doc grant from the research Fund 2022 in the Capital Region of Denmark Grant from Gerhard Linds Foundations"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although emerging evidence supports glutamatergic dysfunction in schizophrenia, clinical trials with glutamatergic compounds have overall been negative. This may be due to changes in glutamate levels during the course of illness. To address this, we measured glutamate levels in dorsal anterior cingulate cortex (dACC) and left thalamus in 57 initially antipsychotic-na\u00efve patients with first-episode psychosis (FEP) aged 22.6\u2009\u00b1\u20095.0 years (58% females) and 55 healthy controls (HC) on a 3T MR scanner at baseline, after six weeks (48 FEP and 53 HC), six months (37 FEP and 49 HC), and two years (35 FEP and 45 HC). Positive and negative symptoms and cognitive function in tests of attention and spatial working memory were assessed at all visits. Linear mixed models were used in statistical analyses. We found lower glutamate levels in dACC in FEP (p\u2009=\u20090.03) that was associated with deficits in attention at all visits (p\u2009&lt;\u20090.05). Thalamic glutamate levels did not differ between groups, but higher levels were related to more pronounced positive symptoms at all visits (p\u2009=\u20090.02). The relation between thalamic glutamate levels and negative symptoms was altered over time (negative symptoms*time: p\u2009=\u20090.003) due to a significant positive association after two years (p\u2009=\u20090.04) but not at other visits. For other metabolites, thalamic NAA were lower in FEP (p\u2009=\u20090.04) and total creatine was increased after 6 weeks treatment (p\u2009=\u20090.01), whereas dACC glx levels were lower after two years (p\u2009=\u20090.02). The results suggest that greater positive symptom severity is related to higher thalamic glutamate levels and cognitive deficits to lower dACC glutamate levels during the first two years of illness. Furthermore, higher thalamic glutamate levels after two years are associated with more severe negative symptomatology. Findings imply that glutamatergic compounds decreasing thalamic and increasing dACC glutamate levels may be beneficial in FEP over the first two years of illness.<\/jats:p>","DOI":"10.1038\/s41380-025-03234-3","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T14:39:08Z","timestamp":1757947148000},"page":"5652-5663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cerebral glutamate levels over two years in initially antipsychotic-na\u00efve first-episode patients with psychosis are related to clinical symptoms and cognition"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7996-3154","authenticated-orcid":false,"given":"Kirsten Borup","family":"Bojesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3647-9709","authenticated-orcid":false,"given":"Cecilie Koldb\u00e6k","family":"Lemvigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Korning","family":"Sigvard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Bitsch","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Bo Wiberg","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egill","family":"Rostrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2590-5055","authenticated-orcid":false,"given":"Bj\u00f8rn Hylsebeck","family":"Ebdrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3056-7262","authenticated-orcid":false,"given":"Birte","family":"Glenth\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"3234_CR1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.biopsych.2021.06.008","volume":"90","author":"J Smucny","year":"2021","unstructured":"Smucny J, Carter CS, Maddock RJ. Medial prefrontal cortex glutamate is reduced in schizophrenia and moderated by measurement quality: a meta-analysis of Proton Magnetic Resonance Spectroscopy studies. Biol Psychiatry. 2021;90:643\u201351.","journal-title":"Biol Psychiatry"},{"key":"3234_CR2","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/s41380-023-01991-7","volume":"28","author":"K Merritt","year":"2023","unstructured":"Merritt K, McCutcheon RA, Aleman A, Ashley S, Beck K, Block W, et al. Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis. Mol Psychiatry. 2023;28:2039\u201348.","journal-title":"Mol Psychiatry"},{"key":"3234_CR3","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41380-021-01297-6","volume":"27","author":"T Nakahara","year":"2022","unstructured":"Nakahara T, Tsugawa S, Noda Y, Ueno F, Honda S, Kinjo M, et al. Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of (1)H-Magnetic Resonance Spectroscopy studies. Mol Psychiatry. 2022;27:744\u201357.","journal-title":"Mol Psychiatry"},{"key":"3234_CR4","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1017\/S0033291719002277","volume":"50","author":"KB Bojesen","year":"2020","unstructured":"Bojesen KB, Ebdrup BH, Jessen K, Sigvard A, Tangmose K, Edden RAE, et al. Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naive patients with psychosis. Psychol Med. 2020;50:2182\u201393.","journal-title":"Psychol Med"},{"key":"3234_CR5","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1038\/npp.2012.113","volume":"37","author":"A Egerton","year":"2012","unstructured":"Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology. 2012;37:2515\u201321.","journal-title":"Neuropsychopharmacology"},{"key":"3234_CR6","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41380-018-0082-9","volume":"23","author":"A Egerton","year":"2018","unstructured":"Egerton A, Broberg BV, Van Haren N, Merritt K, Barker GJ, Lythgoe DJ, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE). Mol Psychiatry. 2018;23:2145\u201355.","journal-title":"Mol Psychiatry"},{"key":"3234_CR7","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00213-016-4318-6","volume":"233","author":"K Beck","year":"2016","unstructured":"Beck K, Javitt DC, Howes OD. Targeting glutamate to treat schizophrenia: lessons from recent clinical studies. Psychopharmacology (Berl). 2016;233:2425\u20138.","journal-title":"Psychopharmacology (Berl)"},{"key":"3234_CR8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamapsychiatry.2014.16","volume":"71","author":"CB Pedersen","year":"2014","unstructured":"Pedersen CB, Mors O, Bertelsen A, Waltoft BL, Agerbo E, McGrath JJ, et al. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry. 2014;71:573\u201381.","journal-title":"JAMA Psychiatry"},{"key":"3234_CR9","doi-asserted-by":"crossref","unstructured":"JD Cohen Cognitive control: core constructs and current considerations. In: T Egner, editor. The Wiley handbook of cognitive control, Chichester, West Sussex, UK: John Wiley & Sons Ltd; 2017. p 3\u2013282017.","DOI":"10.1002\/9781118920497.ch1"},{"key":"3234_CR10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semcdb.2021.02.008","volume":"118","author":"A Caballero","year":"2021","unstructured":"Caballero A, Orozco A, Tseng KY. Developmental regulation of excitatory-inhibitory synaptic balance in the prefrontal cortex during adolescence. Semin Cell Dev Biol. 2021;118:60\u20133.","journal-title":"Semin Cell Dev Biol"},{"key":"3234_CR11","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","volume":"52","author":"JW Olney","year":"1995","unstructured":"Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52:998\u20131007.","journal-title":"Arch Gen Psychiatry"},{"key":"3234_CR12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/jamapsychiatry.2021.0380","volume":"78","author":"K Merritt","year":"2021","unstructured":"Merritt K, McGuire PK, Egerton A, Investigators HMiS, Aleman A, Block W, et al. Association of age, antipsychotic medication, and symptom severity in schizophrenia with proton magnetic resonance spectroscopy brain glutamate level: a mega-analysis of individual participant-level data. JAMA Psychiatry. 2021;78:667\u201381.","journal-title":"JAMA Psychiatry"},{"key":"3234_CR13","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41386-023-01741-x","volume":"49","author":"L Fan","year":"2024","unstructured":"Fan L, Liang L, Wang Y, Ma X, Yuan L, Ouyang L, et al. Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex. Neuropsychopharmacology. 2024;49:845\u201353.","journal-title":"Neuropsychopharmacology"},{"key":"3234_CR14","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1038\/s41380-023-01969-5","volume":"28","author":"M Wang","year":"2023","unstructured":"Wang M, Barker PB, Cascella NG, Coughlin JM, Nestadt G, Nucifora FC Jr, et al. Longitudinal changes in brain metabolites in healthy controls and patients with first episode psychosis: a 7-Tesla MRS study. Mol Psychiatry. 2023;28:2018\u201329.","journal-title":"Mol Psychiatry"},{"key":"3234_CR15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.schres.2018.12.028","volume":"210","author":"NV Kraguljac","year":"2019","unstructured":"Kraguljac NV, Morgan CJ, Reid MA, White DM, Jindal RD, Sivaraman S, et al. A longitudinal magnetic resonance spectroscopy study investigating effects of risperidone in the anterior cingulate cortex and hippocampus in schizophrenia. Schizophr Res. 2019;210:239\u201344.","journal-title":"Schizophr Res"},{"key":"3234_CR16","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgaa072","volume":"2","author":"P Jeon","year":"2021","unstructured":"Jeon P, Limongi R, Ford SD, Mackinley M, Dempster K, Theberge J, et al. Progressive changes in glutamate concentration in early stages of schizophrenia: a longitudinal 7-Tesla MRS Study. Schizophr Bull Open. 2021;2:sgaa072.","journal-title":"Schizophr Bull Open"},{"key":"3234_CR17","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301\u20138.","journal-title":"Am J Psychiatry"},{"key":"3234_CR18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archpsyc.62.9.985","volume":"62","author":"JH Krystal","year":"2005","unstructured":"Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry. 2005;62:985\u201394.","journal-title":"Arch Gen Psychiatry"},{"key":"3234_CR19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/pcn.12823","volume":"73","author":"Y Uno","year":"2019","unstructured":"Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019;73:204\u201315.","journal-title":"Psychiatry Clin Neurosci"},{"key":"3234_CR20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/archgenpsychiatry.2011.1519","volume":"69","author":"LS Kegeles","year":"2012","unstructured":"Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, et al. Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2012;69:449\u201359.","journal-title":"Arch Gen Psychiatry"},{"key":"3234_CR21","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/schbul\/sbx190","volume":"45","author":"MA Reid","year":"2019","unstructured":"Reid MA, Salibi N, White DM, Gawne TJ, Denney TS, Lahti AC. 7T proton magnetic resonance spectroscopy of the anterior cingulate cortex in first-episode schizophrenia. Schizophr Bull. 2019;45:180\u20139.","journal-title":"Schizophr Bull"},{"key":"3234_CR22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41537-019-0080-1","volume":"5","author":"K Merritt","year":"2019","unstructured":"Merritt K, Perez-Iglesias R, Sendt KV, Goozee R, Jauhar S, Pepper F, et al. Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. NPJ Schizophr. 2019;5:12.","journal-title":"NPJ Schizophr"},{"key":"3234_CR23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1017\/S1461145712000314","volume":"16","author":"C de la Fuente-Sandoval","year":"2013","unstructured":"de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M, Favila R, Stephano S, Graff-Guerrero A. Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. Int J Neuropsychopharmacol. 2013;16:471\u20135.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3234_CR24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jamapsychiatry.2013.3939","volume":"71","author":"JR Bustillo","year":"2014","unstructured":"Bustillo JR, Chen H, Jones T, Lemke N, Abbott C, Qualls C, et al. Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. JAMA Psychiatry. 2014;71:265\u201372.","journal-title":"JAMA Psychiatry"},{"key":"3234_CR25","first-page":"611","volume":"43","author":"JR Bustillo","year":"2017","unstructured":"Bustillo JR, Jones T, Chen H, Lemke N, Abbott C, Qualls C, et al. Glutamatergic and neuronal dysfunction in gray and white matter: a Spectroscopic Imaging Study in a Large Schizophrenia Sample. Schizophr Bull. 2017;43:611\u20139.","journal-title":"Schizophr Bull"},{"key":"3234_CR26","first-page":"277","volume":"29","author":"T Chen","year":"2017","unstructured":"Chen T, Wang Y, Zhang J, Wang Z, Xu J, Li Y, et al. Abnormal concentration of GABA and glutamate in the prefrontal cortex in schizophrenia.-An in vivo 1H-MRS Study. Shanghai Arch Psychiatry. 2017;29:277\u201386.","journal-title":"Shanghai Arch Psychiatry"},{"key":"3234_CR27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.biopsych.2010.04.013","volume":"68","author":"MA Reid","year":"2010","unstructured":"Reid MA, Stoeckel LE, White DM, Avsar KB, Bolding MS, Akella NS, et al. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry. 2010;68:625\u201333.","journal-title":"Biol Psychiatry"},{"key":"3234_CR28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199\u2013214.","journal-title":"Arch Gen Psychiatry"},{"key":"3234_CR29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0893-133X(97)00034-1","volume":"17","author":"JD Jentsch","year":"1997","unstructured":"Jentsch JD, Tran A, Le D, Youngren KD, Roth RH. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology. 1997;17:92\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"3234_CR30","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","volume":"281","author":"B Moghaddam","year":"1998","unstructured":"Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281:1349\u201352.","journal-title":"Science"},{"key":"3234_CR31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00213-007-0808-x","volume":"193","author":"N Amitai","year":"2007","unstructured":"Amitai N, Semenova S, Markou A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology (Berl). 2007;193:521\u201337.","journal-title":"Psychopharmacology (Berl)"},{"key":"3234_CR32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00213-004-2127-9","volume":"179","author":"B Greco","year":"2005","unstructured":"Greco B, Invernizzi RW, Carli M. Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU(2\/3) receptor agonist LY379268. Psychopharmacology (Berl). 2005;179:68\u201376.","journal-title":"Psychopharmacology (Berl)"},{"key":"3234_CR33","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.biopsych.2020.06.027","volume":"89","author":"KB Bojesen","year":"2021","unstructured":"Bojesen KB, Broberg BV, Fagerlund B, Jessen K, Thomas MB, Sigvard A, et al. Associations between cognitive function and levels of glutamatergic metabolites and gamma-aminobutyric acid in antipsychotic-naive patients with schizophrenia or psychosis. Biol Psychiatry. 2021;89:278\u201387.","journal-title":"Biol Psychiatry"},{"key":"3234_CR34","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.neuroimage.2009.10.031","volume":"49","author":"Y Shirayama","year":"2010","unstructured":"Shirayama Y, Obata T, Matsuzawa D, Nonaka H, Kanazawa Y, Yoshitome E, et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage. 2010;49:2783\u201390.","journal-title":"Neuroimage"},{"key":"3234_CR35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.schres.2007.05.024","volume":"99","author":"N Rusch","year":"2008","unstructured":"Rusch N, Tebartz van Elst L, Valerius G, Buchert M, Thiel T, Ebert D, et al. Neurochemical and structural correlates of executive dysfunction in schizophrenia. Schizophr Res. 2008;99:155\u201363.","journal-title":"Schizophr Res"},{"key":"3234_CR36","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.239","volume":"6","author":"LM Rowland","year":"2016","unstructured":"Rowland LM, Pradhan S, Korenic S, Wijtenburg SA, Hong LE, Edden RA, et al. Elevated brain lactate in schizophrenia: a 7 T magnetic resonance spectroscopy study. Transl Psychiatry. 2016;6:e967.","journal-title":"Transl Psychiatry"},{"key":"3234_CR37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jpsychires.2006.07.002","volume":"41","author":"P Ohrmann","year":"2007","unstructured":"Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A, et al. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res. 2007;41:625\u201334.","journal-title":"J Psychiatr Res"},{"key":"3234_CR38","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.nicl.2014.03.014","volume":"4","author":"LE Falkenberg","year":"2014","unstructured":"Falkenberg LE, Westerhausen R, Craven AR, Johnsen E, Kroken RA, Berg EML, et al. Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia. Neuroimage Clin. 2014;4:576\u201384.","journal-title":"Neuroimage Clin"},{"key":"3234_CR39","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.schres.2008.08.005","volume":"106","author":"P Ohrmann","year":"2008","unstructured":"Ohrmann P, Kugel H, Bauer J, Siegmund A, Kolkebeck K, Suslow T, et al. Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy. Schizophr Res. 2008;106:156\u201363.","journal-title":"Schizophr Res"},{"key":"3234_CR40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.biopsych.2010.08.024","volume":"69","author":"JR Bustillo","year":"2011","unstructured":"Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, et al. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry. 2011;69:19\u201327.","journal-title":"Biol Psychiatry"},{"key":"3234_CR41","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamapsychiatry.2018.3637","volume":"76","author":"AM Wang","year":"2019","unstructured":"Wang AM, Pradhan S, Coughlin JM, Trivedi A, DuBois SL, Crawford JL, et al. Assessing brain metabolism with 7-T proton magnetic resonance spectroscopy in patients with first-episode psychosis. Jama Psychiat. 2019;76:314\u201323.","journal-title":"Jama Psychiat"},{"key":"3234_CR42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.schres.2020.02.001","volume":"249","author":"M Reddy-Thootkur","year":"2022","unstructured":"Reddy-Thootkur M, Kraguljac NV, Lahti AC. The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders - A systematic review of magnetic resonance spectroscopy studies. Schizophr Res. 2022;249:74\u201384. 2020","journal-title":"Schizophr Res"},{"key":"3234_CR43","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/jmri.22520","volume":"33","author":"RL O\u2019Gorman","year":"2011","unstructured":"O\u2019Gorman RL, Michels L, Edden RA, Murdoch JB, Martin E. In vivo detection of GABA and glutamate with MEGA-PRESS: reproducibility and gender effects. J Magn Reson Imaging. 2011;33:1262\u20137.","journal-title":"J Magn Reson Imaging"},{"key":"3234_CR44","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fpsyt.2018.00438","volume":"9","author":"TK Das","year":"2018","unstructured":"Das TK, Dey A, Sabesan P, Javadzadeh A, Theberge J, Radua J, et al. Putative astroglial dysfunction in schizophrenia: a meta-analysis of (1)H-MRS Studies of Medial Prefrontal Myo-Inositol. Front Psychiatry. 2018;9:438.","journal-title":"Front Psychiatry"},{"key":"3234_CR45","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.pnpbp.2018.03.016","volume":"86","author":"Y Iwata","year":"2018","unstructured":"Iwata Y, Nakajima S, Plitman E, Mihashi Y, Caravaggio F, Chung JK, et al. Neurometabolite levels in antipsychotic-naive\/free patients with schizophrenia: a systematic review and meta-analysis of (1)H-MRS studies. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:340\u201352.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3234_CR46","unstructured":"PECANSII. The Pan European Collaboration on Antipsychotic Na\u00efve Schizophrenia II (PECANSII) study, ClinicalTrials.gov Identifier: NCT02339844: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02339844?term=Glenth%C3%B8j&cond=Schizophrenia&rank=7."},{"key":"3234_CR47","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archpsyc.1990.01810180089012","volume":"47","author":"JK Wing","year":"1990","unstructured":"Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 1990;47:589\u201393.","journal-title":"Arch Gen Psychiatry"},{"key":"3234_CR48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"key":"3234_CR49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0033-3182(95)71666-8","volume":"36","author":"RC Hall","year":"1995","unstructured":"Hall RC. Global assessment of functioning. A modified scale. Psychosomatics. 1995;36:267\u201375.","journal-title":"Psychosomatics"},{"key":"3234_CR50","first-page":"399","volume":"85","author":"BJ Sahakian","year":"1992","unstructured":"Sahakian BJ, Owen AM. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med. 1992;85:399\u2013402.","journal-title":"J R Soc Med"},{"key":"3234_CR51","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0028-3932(98)00036-0","volume":"36","author":"C Lowe","year":"1998","unstructured":"Lowe C, Rabbitt P. Test\/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Cambridge neuropsychological test automated battery. International Study of Post-Operative Cognitive Dysfunction. Neuropsychologia. 1998;36:915\u201323.","journal-title":"Neuropsychologia"},{"key":"3234_CR52","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/mrm.1910300604","volume":"30","author":"SW Provencher","year":"1993","unstructured":"Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672\u20139.","journal-title":"Magn Reson Med"},{"key":"3234_CR53","volume":"34","author":"A Lin","year":"2021","unstructured":"Lin A, Andronesi O, Bogner W, Choi IY, Coello E, Cudalbu C, et al. Minimum Reporting Standards for in vivo Magnetic Resonance Spectroscopy (MRSinMRS): experts\u2019 consensus recommendations. NMR Biomed. 2021;34:e4484.","journal-title":"NMR Biomed"},{"key":"3234_CR54","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/schbul\/sbr069","volume":"39","author":"A Marsman","year":"2013","unstructured":"Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of (1)H-MRS studies. Schizophr Bull. 2013;39:120\u20139.","journal-title":"Schizophr Bull"},{"key":"3234_CR55","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.schres.2020.03.069","volume":"222","author":"M Kubota","year":"2020","unstructured":"Kubota M, Moriguchi S, Takahata K, Nakajima S, Horita N. Treatment effects on neurometabolite levels in schizophrenia: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Schizophr Res. 2020;222:122\u201332.","journal-title":"Schizophr Res"},{"key":"3234_CR56","volume":"16","author":"L Liang","year":"2022","unstructured":"Liang L, Silva AM, Jeon P, Ford SD, MacKinley M, Theberge J, et al. Widespread cortical thinning, excessive glutamate and impaired linguistic functioning in schizophrenia: a cluster analytic approach. Front Hum Neurosci. 2022;16:954898.","journal-title":"Front Hum Neurosci"},{"key":"3234_CR57","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","volume":"75","author":"A Demjaha","year":"2014","unstructured":"Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75:e11\u20133.","journal-title":"Biol Psychiatry"},{"issue":"Suppl 1","key":"3234_CR58","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1055\/s-2006-931483","volume":"39","author":"A Carlsson","year":"2006","unstructured":"Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry. 2006;39(Suppl 1):S10\u20134.","journal-title":"Pharmacopsychiatry"},{"key":"3234_CR59","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2016.05.013","volume":"180","author":"J Pratt","year":"2017","unstructured":"Pratt J, Dawson N, Morris BJ, Grent-\u2018t-Jong T, Roux F, Uhlhaas PJ. Thalamo-cortical communication, glutamatergic neurotransmission and neural oscillations: a unique window into the origins of ScZ? Schizophr Res. 2017;180:4\u201312.","journal-title":"Schizophr Res"},{"key":"3234_CR60","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fnhum.2012.00184","volume":"6","author":"PC Williamson","year":"2012","unstructured":"Williamson PC, Allman JM. A framework for interpreting functional networks in schizophrenia. Front Hum Neurosci. 2012;6:184.","journal-title":"Front Hum Neurosci"},{"key":"3234_CR61","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1017\/S0033291717001271","volume":"48","author":"W Zheng","year":"2018","unstructured":"Zheng W, Li XH, Yang XH, Cai DB, Ungvari GS, Ng CH, et al. Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Psychol Med. 2018;48:72\u201381.","journal-title":"Psychol Med"},{"key":"3234_CR62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.biopsych.2019.07.011","volume":"87","author":"J Kaminski","year":"2020","unstructured":"Kaminski J, Gleich T, Fukuda Y, Katthagen T, Gallinat J, Heinz A, et al. Association of cortical glutamate and working memory activation in patients with schizophrenia: a multimodal proton magnetic resonance spectroscopy and Functional Magnetic Resonance Imaging Study. Biol Psychiatry. 2020;87:225\u201333.","journal-title":"Biol Psychiatry"},{"key":"3234_CR63","volume":"332","author":"JWC Graham","year":"2023","unstructured":"Graham JWC, Jeon P, Theberge J, Palaniyappan L. Non-linear variations in glutamate dynamics during a cognitive task engagement in schizophrenia. Psychiatry Res Neuroimaging. 2023;332:111640.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"3234_CR64","doi-asserted-by":"crossref","DOI":"10.1038\/npjschz.2015.28","volume":"1","author":"R Taylor","year":"2015","unstructured":"Taylor R, Neufeld RW, Schaefer B, Densmore M, Rajakumar N, Osuch EA, et al. Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major depressive disorder: anterior cingulate activity during a color-word Stroop task. NPJ Schizophr. 2015;1:15028.","journal-title":"NPJ Schizophr"},{"key":"3234_CR65","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41380-020-0704-x","volume":"25","author":"K Dempster","year":"2020","unstructured":"Dempster K, Jeon P, MacKinley M, Williamson P, Theberge J, Palaniyappan L. Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate. Mol Psychiatry. 2020;25:1640\u201350.","journal-title":"Mol Psychiatry"},{"key":"3234_CR66","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Ren H, He Y, Li Z, Ma X, Yuan L, et al. Anterior cingulate cortex glutamate levels are related to response to initial antipsychotic treatment in drug-naive first-episode schizophrenia patients. Front Psychiatry. 2020;11:553269.","journal-title":"Front Psychiatry"},{"key":"3234_CR67","doi-asserted-by":"crossref","first-page":"12698","DOI":"10.1523\/JNEUROSCI.1758-13.2013","volume":"33","author":"W Dou","year":"2013","unstructured":"Dou W, Palomero-Gallagher N, van Tol MJ, Kaufmann J, Zhong K, Bernstein HG, et al. Systematic regional variations of GABA, glutamine, and glutamate concentrations follow receptor fingerprints of human cingulate cortex. J Neurosci. 2013;33:12698\u2013704.","journal-title":"J Neurosci"},{"key":"3234_CR68","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","volume":"35","author":"OD Howes","year":"2009","unstructured":"Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull. 2009;35:549\u201362.","journal-title":"Schizophr Bull"},{"key":"3234_CR69","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/schbul\/2.1.19","volume":"2","author":"HY Meltzer","year":"1976","unstructured":"Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976;2:19\u201376.","journal-title":"Schizophr Bull"},{"key":"3234_CR70","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/13543784.12.4.655","volume":"12","author":"PE Keck Jr","year":"2003","unstructured":"Keck PE Jr, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs. 2003;12:655\u201362.","journal-title":"Expert Opin Investig Drugs"},{"key":"3234_CR71","doi-asserted-by":"crossref","first-page":"E367","DOI":"10.1503\/jpn.240094","volume":"49","author":"L Fan","year":"2024","unstructured":"Fan L, Zhang Z, Ma X, Liang L, Wang Y, Yuan L, et al. Glutamate levels and symptom burden in high-risk and first-episode schizophrenia: a dual-voxel study of the anterior cingulate cortex. J Psychiatry Neurosci. 2024;49:E367\u2013E76.","journal-title":"J Psychiatry Neurosci"},{"key":"3234_CR72","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1192\/bjp.bp.106.033670","volume":"191","author":"J Theberge","year":"2007","unstructured":"Theberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry. 2007;191:325\u201334.","journal-title":"Br J Psychiatry"},{"key":"3234_CR73","first-page":"703","volume":"9","author":"KB Bojesen","year":"2024","unstructured":"Bojesen KB, Rostrup E, Sigvard AK, Mikkelsen M, Edden RAE, Ebdrup BH, et al. The trajectory of prefrontal GABA levels in initially antipsychotic-naive patients with psychosis during two years treatment and associations with striatal cerebral blood flow and outcome. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9:703\u201313. 2023","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"3234_CR74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033291723000144","volume":"53","author":"KB Bojesen","year":"2023","unstructured":"Bojesen KB, Glenthoj BY, Sigvard AK, Tangmose K, Raghava JM, Ebdrup BH, et al. Cerebral blood flow in striatum is increased by partial dopamine agonism in initially antipsychotic-naive patients with psychosis. Psychol Med. 2023;53:1\u201311.","journal-title":"Psychol Med"},{"key":"3234_CR75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11064-013-1199-5","volume":"39","author":"CD Rae","year":"2014","unstructured":"Rae CD. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem Res. 2014;39:1\u201336.","journal-title":"Neurochem Res"},{"key":"3234_CR76","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature09613","volume":"468","author":"D Attwell","year":"2010","unstructured":"Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, Newman EA. Glial and neuronal control of brain blood flow. Nature. 2010;468:232\u201343.","journal-title":"Nature"},{"key":"3234_CR77","first-page":"137","volume":"9","author":"J Smucny","year":"2024","unstructured":"Smucny J, Carter CS, Maddock RJ. Greater choline-containing compounds and myo-inositol in treatment-resistant versus responsive schizophrenia: a (1)H-Magnetic Resonance Spectroscopy Meta-analysis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9:137\u201345.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"3234_CR78","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.5071","volume":"37","author":"K Kanagasabai","year":"2024","unstructured":"Kanagasabai K, Palaniyappan L, Theberge J. Precision of metabolite-selective MRS measurements of glutamate, GABA and glutathione: a review of human brain studies. NMR Biomed. 2024;37:e5071.","journal-title":"NMR Biomed"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03234-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03234-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03234-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:10:39Z","timestamp":1762884639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03234-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":78,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3234"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-03234-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.04.10.25325581","asserted-by":"object"}]},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Bojesen received lecture fees from Lundbeck Pharma A\/S. Dr. Glenth\u00f8j was the head of the Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) from January 2009 to December 2021, which was partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them. She has no other conflicts to disclose. Dr. Ebdrup is part of the Advisory Board of Eli Lilly Denmark A\/S, Janssen-Cilag, Lundbeck Pharma A\/S, and Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company, and Lundbeck Pharma A\/S. The rest of the authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}